StockData
Black Diamond Therapeutics, Inc. logo

Black Diamond Therapeutics, Inc. (BDTX) stock

BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$1.44−0.09 (-5.88%)

Close on Nov 17, 2026Market cap $82.73MP/E –Yield –

Black Diamond Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Black Diamond Therapeutics's price to book ratio was 1.0× on Nov 11, 2026, against 1.7× a year earlier. Over the last 5 years it ranged from 0.4× to 3.1×, with a median of 1.1×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.0×−0.1
2025Dec 31, 20251.1×−0.1
2024Dec 31, 20241.2×+0.2
2023Dec 29, 20231.1×+0.6
2022Dec 30, 20220.5×−0.4
2021Dec 31, 20210.9×−2.6
2020Dec 31, 20203.5×–

More Black Diamond Therapeutics figures

See a number that looks wrong?